AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 02:53:22 2024-05-17 pm EDT			5-day change	1st Jan Change
0.0111 ^USD	+11.20%		+5.71%	-41.58%

Apr. 16	AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	CI

AXIM Biotechnologies, Inc. Announces Addition of Donald Abrams to its Advisory board

May 09, 2017 at 09:00 am EDT

AXIM Biotechnologies, Inc. announced the addition to its advisory board of Dr. Donald Abrams, chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco.

Latest news about AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	Mar. 14	CI
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	Feb. 20	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.	Dec. 25	CI
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production	Dec. 20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease	23-09-12	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	23-08-01	CI
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	23-07-12	CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding	23-05-31	CI
AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer	23-05-23	CI
AXIM Biotechnologies, Inc. announced that it has received $0.575 million in funding	23-05-22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance	23-01-17	CI
AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent	22-12-13	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
AXIM Biotechnologies, Inc. Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch	22-10-04	CI
Axim® Biotechnologies Signs Exclusive Global Commercialization Agreement with Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions	22-09-19	CI
Insider Buy: Axim Biotechnologies	22-08-31	MT
AXIM Biotechnologies, Inc. announced that it has received $0.1 million in funding	22-08-28	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.1 million in funding	22-08-23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI

Chart AXIM Biotechnologies, Inc.

Duration

Period

More charts

Company Profile

Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AXIM BIOTECHNOLOGIES, INC.	-41.58%	2.78M
MODERNA, INC.	+33.01%	50.85B
IQVIA HOLDINGS INC.	+0.05%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.74%	19.13B
BIO-TECHNE CORPORATION	+8.55%	13.05B
MEDPACE HOLDINGS, INC.	+27.91%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.30%	12.08B

Other Biotechnology & Medical Research